DURELLI, Luca

DURELLI, Luca  

SCIENZE CLINICHE E BIOLOGICHE  

Mostra records
Risultati 1 - 20 di 182 (tempo di esecuzione: 0.045 secondi).
Titolo Data di pubblicazione Autore(i) File
IL 6, IL 10 IL 12, TNF-alpha anf IFN-gamma serum levels in secondary progressive multiple sclerosis patients treated with ifn-beta 1b and azathioprine or placebo: a two-year prospective study 2007 J. MANDRIOLI; R. BEDIN; L. MANNESCHI; I. PESCI; E. MONTANARI; L. MOTTI; L. PROVINCIALI; E. SCARPINI; D. CAPUTO; M.R. TOLA; M.G. MARROSU; A. GHEZZI; P. CAVALLA; L. DURELLI; E. MERELLI
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 2006 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 2006 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A case of canomad (chronic ataxic neuropathy, ophthalmoplegia, igm paraprotein, cold agglutinins and disialosyl antibodies) with transient cognitive impairment. 2004 F. MELIS; M. REGGIANI; E. TREVISAN; P. BARBERO; M. IUDICELLO; R. SCIOLLA; L. DURELLI
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 2009 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes 2006 M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis 2006 M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis 2005 E. Festa; P. Barbero; A. Pipieri; M. Bergui; A. Boghi; G. Bradac; L. Giordano; L. Durelli
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 2004 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 2011 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMISED EVALUATION); study: preliminary safety and tolerability data from a 2-year double-blind, randomised, multicentre, pilot study. 2004 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; R. TOLA; D. CAPUTO; A.GHEZZI; E. SCARPINI; G. MEOLA; L. DURELLI
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomised, multicentre, pilot study. 2005 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; P. CAVALLA; L. PROVINCIALI; M.G. MARROSU; L. DURELLI
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomized, multicentre, pilot study. 2005 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; L. PROVINCIALI; P. CAVALLA; M.G. MARROSU; L. DURELLI; AND THE ITALIAN A.S.P.I.R.E. GROUP
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION), study: preliminary safety and tolerability data from a 2-year double blind, randomized, multicentre, pilot study 2004 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; L. DURELLI; THE ITALIAN A.S.P.I.R.E. GROUP
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 2016 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 2016 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 2005 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 2003 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
ASPIRE ( Azathioprine Secondary Progressive Interferon treated patients Randomised Evaluation) study: 2-year double-blind and 1-year open, randomised, multicentre, pilot study. Multiple Sclerosis Functional Composite (MSFC) and magnetic resonance data 2009 E Montanari; L Manneschi; I Pesci; L Motti; E Marelli; MR Tola; D Caputo; L Provinciali; E Scarpini; MG Marrosu; A Ghezzi; P Cavalla; L. Durelli